According to the SEC Form 4 filings, PAUL STEVEN M, being in a position of
No biography is available at this moment.
Buys | $974,278 | 1 | 100 |
Sells | $0 | 0 | 0 |
| 2026-10-22 | Rapport Therapeutics, Inc. Common Stock RAPP | director | 35,714 0.0765% | $27.28 | $974,278 | -4.9% | ||
| 2025-09-12 | Rapport Therapeutics, Inc. Common Stock RAPP | director | 41,666 0.0934% | $24.65 | $1.03M | +27.29% | ||
| 2022-04-01 | Sale | Alnylam Pharmaceuticals, Inc. ALNY | 90 <0.0001% | $174.33 | $15,690 | +18.01% | ||
| 2020-12-18 | Sale | Alnylam Pharmaceuticals, Inc. ALNY | director | 15,000 0.0128% | $140.00 | $2.1M | +19.4% | |
| 2020-02-10 | Sale | Alnylam Pharmaceuticals, Inc. ALNY | director | 30,000 0.0263% | $130.00 | $3.9M | +3.18% | |
| 2016-01-14 | Voyager Therapeutics, Inc. VYGR | President and CEO | 20,000 0.0801% | $14.07 | $281,380 | -11.93% | ||
| 2015-01-26 | Alnylam Pharmaceuticals, Inc. ALNY | director | 2,000 0.0024% | $95.00 | $190,000 | +10.44% | ||
| 2008-02-04 | Sale | Eli Lilly and Company LLY | EVP, Science and Technology | 19,822 0.0018% | $51.60 | $1.02M | -7.33% | |
| 2007-03-12 | Sale | Eli Lilly and Company LLY | EVP, Science and Technology | 7,289 0.0007% | $52.39 | $381,871 | +6.88% | |
| 2007-02-12 | Sale | Eli Lilly and Company LLY | EVP, Science and Technology | 7,290 0.0007% | $54.38 | $396,430 | +4.53% | |
| 2007-02-08 | Sale | Eli Lilly and Company LLY | EVP, Science and Technology | 10,092 0.0009% | $54.32 | $548,234 | +4.9% | |
| 2006-10-20 | Sale | Eli Lilly and Company LLY | EVP, Science and Technology | 4,836 0.0004% | $56.91 | $275,217 | -0.35% | |
| 2006-04-25 | Sale | Eli Lilly and Company LLY | EVP, Science and Technology | 25,000 0.0023% | $52.06 | $1.3M | +6.21% | |
| 2006-04-21 | Sale | Eli Lilly and Company LLY | EVP, Science and Technology | 25,000 0.0023% | $52.80 | $1.32M | +4.71% | |
| 2006-02-02 | Sale | Eli Lilly and Company LLY | EVP, Science and Technology | 6,201 0.0006% | $57.00 | $353,457 | -0.73% |